Adverse Reactions of First-Line Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma Treatment: A Descriptive Analysis From WHO-VigiAccess [PDF]
International Journal of HepatologyConclusion: While gastrointestinal toxicities were class-wide concerns, agent-specific risks necessitate tailored monitoring. These findings emphasized the need for vigilant monitoring and personalized management in clinical practice.
Wei fan Sui +5 more
doaj +5 more sources
Adverse reactions of four multi-targeted tyrosine kinase inhibitors: a descriptive analysis of the WHO-VigiAccess database [PDF]
Frontiers in PharmacologyBackgroundThe introduction of multi-targeted tyrosine kinase inhibitors (MTKIs) such as axitinib, lenvatinib, sorafenib, and sunitinib has greatly broadened the available treatment options for Renal Cell Carcinoma (RCC).
Lijun Li +5 more
exaly +6 more sources
Adverse events of hepatic anti-fibrotic agents in phase 3 and above clinical trials: a descriptive analysis of the WHO-VigiAccess database [PDF]
Frontiers in PharmacologyIntroductionLiver fibrosis is a pathological condition in response to chronic liver injuries. Currently, there is no Food and Drug Administration (FDA) approved pharmacotherapy for liver fibrosis.
Yuwei Liu
exaly +6 more sources
A real-world data analysis of ocular adverse events linked to anti-VEGF drugs: a WHO-VigiAccess study [PDF]
Frontiers in PharmacologyIntroductionVascular endothelial growth factor (VEGF) is key to wet age-related macular degeneration (wAMD). Anti-VEGF drugs are the main treatment in clinics.
Chen Li +3 more
exaly +6 more sources
Adverse event profile of five anti head and neck squamous cell carcinoma drugs: a descriptive analysis from WHO-VigiAccess [PDF]
Frontiers in PharmacologyBackgroundHead and neck squamous cell carcinoma (HNSCC) remains a significant global health concern, with treatment outcomes for advanced or metastatic stages being suboptimal despite the availability of various targeted therapies and immunotherapies ...
Weimin Gao +3 more
exaly +6 more sources
Assessing the real-world safety of vutrisiran for transthyretin-mediated amyloidosis with polyneuropathy: Based on WHO-VigiAccess and FAERS databases. [PDF]
PLoS ONEBackgroundVutrisiran is a double-stranded siRNA targeting transthyretin mRNA, primarily for the treatment of transthyretin-mediated amyloidosis (ATTR) with polyneuropathy.
Weiwei Tong +8 more
doaj +3 more sources
Characterization of adverse reactions to four common targeted drugs for hepatocellular carcinoma in WHO-VigiAccess [PDF]
Scientific ReportsHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality, with limited therapeutic options available for advanced stages of the disease.
Zeyu Wang, Jiyao Sheng, Xuewen Zhang
doaj +4 more sources
Pharmacovigilance analysis of cutaneous adverse drug reactions for cetuximab, panitumumab, and necitumumab based on EudraVigilance and WHO VigiAccess [PDF]
Frontiers in PharmacologyIntroductionAnti-EGFR monoclonal antibodies (mAbs)--cetuximab, panitumumab, and necitumumab--are cornerstone therapies for selected solid tumors but are frequently associated with cutaneous adverse drug reactions (ADRs).
Natalia Sauer +4 more
doaj +4 more sources
Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess [PDF]
Frontiers in PharmacologyIntroductionEnfortumab vedotin (EV) and Erdafitinib are effective therapeutic drugs for bladder cancer patients following post-chemotherapy and immunotherapy.
Yuanbin Huang +9 more
doaj +4 more sources
A real-world study of ublituximab based on the WHO-VigiAccess and U.S. food and drug administration’s adverse event reporting system databases [PDF]
Frontiers in ImmunologyObjectiveThe study bridge statistical pharmacovigilance signals to clinically actionable insights by systematically characterizing adverse event (AE) patterns associated with ublituximab and identifying previously unrecognized risks.
Jiagnang Cao, Qinguo Shen, Yan Zou
doaj +4 more sources